# The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

> **NCT07065968** · PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 132 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07065968
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-19
- **Primary completion:** 2027-09-10
- **Final completion:** 2027-12-30
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07065968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07065968, "The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07065968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*